Zimmer Biomet Holdings, Inc. (ZBH)
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.
Zimmer Biomet beats profit estimates on strong demand for medical devices
Zimmer Biomet Holdings beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Zimmer (ZBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet: Brighter Prospects In H2 2024
Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates. Demographics, the rise of ASCs and technological advancements should be supportive of long-term growth. Zimmer Biomet also expects new product launches to accelerate growth in the second half of 2024.
